Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Infectious Disease

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1551518

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1551518

Aspergillosis Drugs

PUBLISHED:
PAGES: 373 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global Aspergillosis Drugs Market to Reach US$3.9 Billion by 2030

The global market for Aspergillosis Drugs estimated at US$3.3 Billion in the year 2023, is expected to reach US$3.9 Billion by 2030, growing at a CAGR of 2.4% over the analysis period 2023-2030. Acute Aspergillosis Drugs, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$3.2 Billion by the end of the analysis period. Growth in the Chronic Aspergillosis Drugs segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$897.4 Million While China is Forecast to Grow at 4.9% CAGR

The Aspergillosis Drugs market in the U.S. is estimated at US$897.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$775.7 Million by the year 2030 trailing a CAGR of 4.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Global Aspergillosis Drugs Market - Key Trends and Drivers Summarized

What Is Aspergillosis and How Are Drugs Used to Combat It?

Aspergillosis is a fungal infection caused by the Aspergillus species, which can range from a benign, asymptomatic condition to a severe, life-threatening disease. This infection primarily affects the lungs but can also spread to other organs, especially in immunocompromised individuals. The management of aspergillosis involves a range of antifungal drugs designed to target the Aspergillus fungus and control its growth. The treatment strategy varies depending on the type of aspergillosis, such as invasive aspergillosis, chronic pulmonary aspergillosis, or allergic bronchopulmonary aspergillosis (ABPA). For invasive cases, systemic antifungal agents like voriconazole and amphotericin B are commonly used, while chronic and allergic forms may be treated with itraconazole or corticosteroids in addition to antifungals. The choice of medication is influenced by factors such as the patient's overall health, the specific Aspergillus species involved, and the severity of the infection. As the understanding of aspergillosis evolves, so does the development of more effective and targeted antifungal therapies.

What Are the Key Antifungal Agents for Treating Aspergillosis?

The treatment landscape for aspergillosis includes several key antifungal agents, each with unique mechanisms of action and therapeutic profiles. Voriconazole, a triazole antifungal, is often the first-line treatment for invasive aspergillosis due to its potent activity against a wide range of Aspergillus species. It works by inhibiting the synthesis of ergosterol, an essential component of the fungal cell membrane. Amphotericin B, an older but still commonly used drug, acts by binding to ergosterol in the fungal cell membrane, creating pores that lead to cell death. Newer triazoles, such as posaconazole and isavuconazole, have also emerged, offering extended-spectrum activity and improved safety profiles compared to earlier agents. Echinocandins, like caspofungin, are another class of antifungals used in some cases of aspergillosis, particularly when other treatments fail or in combination therapy. These drugs interfere with the synthesis of beta-glucan, a crucial component of the fungal cell wall. The choice of antifungal therapy often depends on factors like the drug’s spectrum of activity, potential side effects, and patient-specific considerations.

How Are Treatment Protocols Evolving in Response to Drug Resistance and Other Challenges?

Aspergillosis treatment protocols are continuously evolving in response to challenges such as drug resistance and the need for personalized therapy. Drug resistance is a growing concern, with some Aspergillus strains showing reduced susceptibility to commonly used antifungals like voriconazole. This has led to increased use of newer antifungal agents and combination therapies to enhance efficacy and overcome resistance. Additionally, there is a push towards developing more targeted therapies and novel antifungal compounds to address the limitations of existing treatments. Personalized medicine is becoming more prominent, with advancements in genomic and diagnostic technologies allowing for more precise identification of fungal strains and their resistance profiles. This enables clinicians to tailor treatment regimens based on the specific characteristics of the infection and the patient. The increasing use of molecular diagnostics and biomarkers is improving the accuracy of diagnoses and the effectiveness of treatment strategies, helping to address the complexities associated with aspergillosis management.

What Drives the Growth in the Aspergillosis Drugs Market?

The growth in the aspergillosis drugs market is driven by several factors. Advances in antifungal drug development are a key factor, with ongoing research and innovation leading to the introduction of new agents with improved efficacy and safety profiles. The rising incidence of aspergillosis, particularly among immunocompromised populations such as cancer patients and organ transplant recipients, is also contributing to increased demand for effective treatments. Drug resistance is another significant driver, as the need for novel therapies and combination treatment options intensifies. The expansion of diagnostic technologies that allow for faster and more accurate detection of aspergillosis is further fueling market growth, as early diagnosis can significantly impact treatment outcomes. Additionally, growing awareness and improved understanding of aspergillosis and its management are leading to better disease management practices and increased adoption of advanced therapies. The combination of these factors reflects a dynamic market that is evolving in response to both clinical needs and technological advancements.

Select Competitors (Total 43 Featured) -

  • Asahi Kasei Pharma Corporation
  • Astellas Pharma US, Inc.
  • Astellas Pharma, Inc.
  • Basilea Pharmaceutica Ltd.
  • Bioseutica
  • Endo International PLC
  • F2G
  • Matinas BioPharma Holdings, Inc.
  • Mayne Pharma Group Ltd.
  • Merck & Co., Inc.
  • Pulmatrix, Inc.
  • Pulmocide
  • SCYNEXIS, Inc.
  • Shionogi & Co., Ltd.
  • TFF Pharmaceuticals, Inc. ;
Show more
Product Code: MCP26748

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Aspergillosis Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Aspergillosis Among Immunocompromised Patients Spurs Demand for Innovative Therapies
    • Advancements in Antifungal Drug Development Expands Addressable Market Opportunity for Aspergillosis Treatments
    • Integration of Targeted and Personalized Medicine Drives Adoption of Advanced Aspergillosis Drugs
    • Rising Awareness and Early Diagnosis of Aspergillosis Accelerates Growth in Drug Market
    • Emergence of Combination Therapies Strengthens Business Case for Enhanced Efficacy in Aspergillosis Treatment
    • Focus on Drug Resistance and New Therapeutic Approaches Drives Demand for Effective Treatments
    • Expansion of Healthcare Access in Emerging Markets Impacts Aspergillosis Drug Distribution
    • Innovations in Drug Delivery Systems Generate Opportunities for Enhanced Aspergillosis Therapy
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Aspergillosis Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Aspergillosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Aspergillosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Aspergillosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Acute Aspergillosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Acute Aspergillosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Acute Aspergillosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chronic Aspergillosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chronic Aspergillosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chronic Aspergillosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Antifungal Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Antifungal Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Antifungal Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Corticosteroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Corticosteroid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Corticosteroid Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Aspergillosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • JAPAN
    • Aspergillosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CHINA
    • Aspergillosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • EUROPE
    • Aspergillosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Aspergillosis Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Aspergillosis Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Aspergillosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • FRANCE
    • Aspergillosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: France 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • GERMANY
    • Aspergillosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Aspergillosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Spain 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Russia 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Europe 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Aspergillosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Aspergillosis Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Aspergillosis Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Asia-Pacific 16-Year Perspective for Aspergillosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Aspergillosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Australia 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • INDIA
    • Aspergillosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: India 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: India 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: India 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: South Korea 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Aspergillosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Aspergillosis Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Aspergillosis Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Latin America 16-Year Perspective for Aspergillosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Argentina 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Brazil 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Mexico 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Rest of Latin America 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Aspergillosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Aspergillosis Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Aspergillosis Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Middle East 16-Year Perspective for Aspergillosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Iran 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Israel 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Saudi Arabia 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: UAE 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: Rest of Middle East 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • AFRICA
    • Aspergillosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Aspergillosis Drugs by Disease Type - Acute Aspergillosis and Chronic Aspergillosis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Africa 16-Year Perspective for Aspergillosis Drugs by Disease Type - Percentage Breakdown of Value Sales for Acute Aspergillosis and Chronic Aspergillosis for the Years 2014, 2024 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Aspergillosis Drugs by Drug Class - Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Aspergillosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Antifungal Drugs, Corticosteroid Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Aspergillosis Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Aspergillosis Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!